前收市價 | 6.00 |
開市 | 6.00 |
買盤 | 2.05 |
賣出價 | 3.00 |
拍板 | 140.00 |
到期日 | 2025-06-20 |
今日波幅 | 6.00 - 6.00 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 55 |
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca
(Bloomberg) -- The Food and Drug Administration delayed a breast- and lung-cancer trial of an experimental treatment that BioNTech SE licensed from Chinese biotech MediLink Therapeutics Ltd., citing safety concerns.Most Read from BloombergFlesh-Eating Bacteria That Can Kill in Two Days Spreads in JapanS&P 500 Hits 30th Record of 2024 as Megacaps Rally: Markets WrapThese Are the World’s Most Expensive Cities for Expats in 2024Hedge Funds’ Secret Weapon to Fight the SEC Lives in TexasHow the US Mo
A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?